

Cover Story
NCI Director's Report
By Matthew Bin Han Ong
The gridlock in Washington is taking a toll on federally funded cancer research as the partisan wrangling in Congress over border security and funding for Israel and Ukraine shows no sign of relenting.
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets
NCI Trials


NCI Trials for December 2023
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Caught in the crossfire: The critical threats facing cancer centers, research, and patient care
- Columbia’s cancer center becomes collateral damage in Trump’s war on antisemitism
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- Trump’s tariffs will likely affect cancer drugs and devices—and may deepen drug shortages
- The University of Rochester Wilmot Cancer Institute earns NCI Cancer Center designation